Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer

Cancer Science

Volumn 100, Issue 5, 2009, Pages 914-919

  Tamura, Kenji ^a,b   Furihata, Mutsuo ^b   Chung, Su Yong ^a   Uemura, Motohide ^a   Yoshioka, Hiroki ^a   Iiyama, Tatsuo ^b   Ashida, Shingo ^b   Nasu, Yasutomo ^c   Fujioka, Tomoaki ^d   Shuin, Taro ^b   Nakamura, Yusuke ^a   Nakagawa, Hidewaki ^a,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b KOCHI UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

^e RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCALCIN; STANNIOCALCIN 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CASTRATION; CELL CYCLE ARREST; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

CASTRATION; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATIC NEOPLASMS; RNA INTERFERENCE;

EID: 65349172979     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01117.x     Document Type: Article

References (21)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859-64.
2. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: What do they suggest? Epidemiol Rev 2001; 23: 3-13.
3. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
4. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2006; 23: 8253-61.
5. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166: 416-19.
6. Tamura K, Furihata M, Tsunoda T et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007; 67: 5117-25.
7. Wagner GF, Milliken C, Friesen HG et al. Studies on the regulation and characterization of plasma stanniocalcin in rainbow trout. Mol Cell Endocrinol 1991; 79: 129-38.
8. Wagner GF, Jaworski E. Calcium regulates stanniocalcin mRNA levels in primary cultured rainbow trout corpuscles of stannius. Mol Cell Endocrinol 1994; 99: 315-22.
9. Chang AC, Janosi J, Hulsbeek M et al. A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol 1995; 112: 241-7.
10. Ishibashi K, Miyamoto K, Taketani Y et al. Molecular cloning of a second human stanniocalcin homologue (STC2). Biochem Biophys Res Commun 1998; 250: 252-8.
11. Ashida S, Furihata M, Katagiri T et al. Expression of novel molecules, MICAL2-PV (mical2 prostate cancer variants), increases with high Gleason score and prostate cancer progression. Clin Cancer Res 2006; 12: 2767-73.
12. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus predonisone or mitoxantrone plus predonisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
13. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and predonisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
14. Moore EE, Keuetner RE, Conklin DC et al. Stanniocalcin 2: characterization of the protein and its localization to human pancreatic α cells. Horm Metab Res 1999; 31: 406-14.
15. True L, Coleman I, Hawley S et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006; 103: 10991-6.
16. Peehl DM, Coram M, Khine H et al. The significance of monoamine oxidase-A expression in high grade prostate cancer. J Urol 2008; 180: 2206-11.
17. Tomlins SA, Mehra R, Rhodes DR et al. Integrative molecular concept modeling of prostate cancer. Nat Genet 2007; 39: 41-51.
18. Law AY, Lai KP, Ip CK et al. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp Cell Res 2008; 314: 1823-30.
19. Meyer HA, Tölle A, Jung M et al. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol 2008 published online 09 April 2008.
20. Hirota E, Yan L, Tsunoda T et al. Genome-wide gene expression profiles of clear cell renal cell carcinoma: Identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol; 29: 799-827.
21. Ito D, Walker JR, Thompson CS et al. Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol 2004; 24: 9456-69.